Twist Bioscience approves stock increase, officer exculpation
Twist Bioscience Corporation (NASDAQ:TWST), a synthetic DNA specialist with a market capitalization of $2.8 billion, recently held its Annual Meeting of Stockholders, resulting in significant ...
Victory Capital reports $176.5 billion in AUM
SAN ANTONIO - Victory Capital Holdings, Inc. (NASDAQ: NASDAQ:VCTR), a global asset management firm, has announced its latest figures for Assets Under Management (AUM), reporting a total of $176.5 ...
JFrog CEO Shlomi Ben Haim sells shares worth $652,875
JFrog Ltd (NASDAQ:FROG), a software company with impressive gross profit margins of 78% and strong financial health according to InvestingPro, reported that CEO Shlomi Ben Haim recently sold 17,775 ...
Twist Bioscience director Robert Chess sells shares totaling $156,216
Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), a $2.8 billion market cap biotechnology company with a Fair overall financial health rating according to InvestingPro, recently sold 2, ...
Wedbush cuts PANW stock price target to $225, maintains outperform
Wedbush Securities adjusted its price target for Palo Alto Networks (NASDAQ:PANW) shares, reducing it from the previous $400.00 to $225.00, while retaining an Outperform rating for the cybersecurity ...
Morgan Stanley raises Victory Capital stock price target to $68
Morgan Stanley (NYSE:MS) adjusted its outlook for Victory Capital Holdings, Inc. (NASDAQ: NASDAQ:VCTR), increasing the firm's price target from $63.00 to $68.00. The investment bank maintained its ...
KeyBanc raises Palo Alto Networks target to $240
KeyBanc Capital Markets adjusted its outlook on Palo Alto Networks (NASDAQ:PANW) shares, increasing the price target to $240 from the previous $217 while maintaining an Overweight rating on the stock.
Barclays lifts Baidu stock price target to $95 on ADR re-rating
Barclays (LON:BARC) maintained its Equalweight rating on Baidu (NASDAQ:BIDU) stock but increased the price target to $95.00 from the previous $83.00. The adjustment reflects a re-rating of the broader ...
Goldman Sachs lifts monday.com stock target to $400, maintains Buy
Goldman Sachs adjusted its outlook on monday.com Ltd. (NASDAQ:MNDY) shares, increasing the price target to $400 from the previous $350, while reiterating a Buy rating on the stock. The stock, ...
Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)
Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.
CyberArk Software (CYBR) to Release Earnings on Thursday
CyberArk Software (NASDAQ:CYBR – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect CyberArk Software to post ...